FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to immunocytokines, which contain a cytokine or a variant thereof, located in the hinge portion of the heavy chain of the antibody or in the hinge portion between the antigen-binding fragment and the subunit of the Fc domain or part thereof. Also disclosed is a nucleic acid coding said immunocytokine, a pharmaceutical formulation and use of immunocytokine.
EFFECT: invention is effective for regulation of immune responses.
27 cl, 16 dwg, 27 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
